Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

133.85EUR
23 May 2018
Change (% chg)

€0.30 (+0.22%)
Prev Close
€133.55
Open
€133.55
Day's High
€134.30
Day's Low
€132.00
Volume
62,141
Avg. Vol
118,836
52-wk High
€137.35
52-wk Low
€97.24

Summary

Name Age Since Current Position

Marc de Garidel

60 2016 Non-Executive Chairman

David Meek

54 2017 Chief Executive Officer, Director

Antoine Flochel

53 2005 Vice Chairman of the Board

Aymeric le Chatelier

48 2016 Chief Financial Officer, Executive Vice President

Regis Mulot

51 2018 Chief Human Resource Officer, Executive Vice President

Alexandre LeBeaut

60 2017 Executive Vice President Research & Development, Chief Scientific Officer

Dominique Laymand

63 2017 Executive Vice President, Chief Ethics and Compliance Officer

Francois-Maurice Garnier

55 2014 Executive Vice President, General Counsel

Dominique Bery

47 2018 Executive Vice President, Strategy & Transformation

Benoit Hennion

42 2017 Executive Vice President and President, Consumer Healthcare

Ivana Magovcevic-Liebisch

50 2018 Executive Vice President, Chief Business Officer

Aidan Murphy

51 2018 Executive Vice-President, Technical Operations

Richard Paulson

50 2018 Executive Vice President and Chief Executive Officer of Ipsen North America

Harout Semerjian

47 2017 Executive Vice President & President, Specialty Care International & Global Franchises

Christopher Masterson

Senior Vice President, Quality

Didier Veron

2013 Senior Vice President, Public Affairs and Corporate Communication

Eugenia Litz

2016 Vice President of Investor Relations

Heather White

2014 Vice President, Global Internal Audit

Christophe Jean

61 2018 Special Advisor to the CEO

Anne Beaufour

54 2005 Director

Henri Beaufour

53 2005 Director

Philippe Bonhomme

48 2012 Director - Representative of Mayroy SA

Christophe Verot

57 2011 Director

Carol Xueref

62 2017 Director

Helene Auriol-Potier

55 2017 Independent Director

Herve Couffin

66 2005 Independent Director

Margaret Liu

61 2017 Independent Director

Pierre Martinet

68 2005 Independent Director

Michele Ollier

59 2015 Independent Director

Carol Stuckley

62 2017 Independent Director

Biographies

Name Description

Marc de Garidel

Mr. Marc de Garidel serves as Non-Executive Chairman of Ipsen SA. He serves as Non-Executive Chairman at the firm since November 22, 2010. He was Chief Executive Officer of Ipsen SA from November 22, 2010 to July 18, 2016. He is also Member of the Company's Strategic Committee. Until August 2014, he oversaw as General Manager the Company's United States Endocrinology/Oncology Business Unit. Mr. de Garidel started his career in 1983 with the Eli Lilly pharmaceutical Group. He held various roles, mainly Finance related, firstly in France, then in the United States and in Germany. In 1995, he joined Amgen, the American biotech Group, as Vice President, Finance and Treasury for Europe. In 1998, he was appointed at Amgen's headquarters in California as Vice President, Corporate Controller and Chief Accounting Officer. In 2000, he became Vice President, General Manager for France, in charge of general management of Amgen France. In 2006, he was appointed Vice President of Southwestern Europe comprising France, Spain, Belgium, and Portugal. In addition, he served as President of the Biotech Committee of the French Pharmaceuticals Association from 2003 to 2006. He was appointed Vice President from 2006 and President in 2010 of European Biopharmaceutical Enterprises. He holds a teaching position at Ecole Centrale de Paris and at ESSEC Business School since 2008 and was awarded with the title of a Chevalier de la Legion d'Honneur. Mr. de Garidel currently also holds the posts of Chairman of Ipsen Pharma SAS, Suraypharm SAS and G5 Sante, as well as Non-Executive Chairman of Promethera. He graduated from Ecole Superieure des Travaux Publics with a degree in Civil Engineering and he also obtained a Business degree at Thunderbird School of Global Management in Arizona, the United States.

David Meek

Mr. David Meek serves as Chief Executive Officer, Director of IPSEN SA. He is Chief Executive Officer at IPSEN SA since July 18, 2016 and Director since June 7, 2017. He has over 25 years of experience in the pharmaceutical industry where he held various global executive positions in major pharmaceutical and biotechnology companies. Most recently, he was Executive Vice-President and President of the oncology division of Baxalta Inc., which was recently acquired by Shire. He led the formation of the oncology division and rapidly created an innovative oncology portfolio through strategic acquisitions and partnering deals. He started his career at Johnson & Johnson and Janssen Pharmaceutica (1989-2004) where he held a variety of U.S. senior sales and marketing positions across multiple therapeutic areas in primary care (gastroenterology, pain management, dermatology) and specialty care (oncology, neuroscience). He then joined Novartis (2005-2012), where he successively served as the global business franchise head for the company’s respiratory and dermatology franchise in Basel, Switzerland; President and Chief Executive Officer of the pharmaceutical division in Canada; and the head of oncology for Northern, Central and Eastern Europe, based in Milan, Italy. From 2012 to 2014, he served as Chief Commercial Officer of Endocyte, an American biotechnology company. He holds a BA in Management from the University of Cincinnati.

Antoine Flochel

Mr. Antoine Flochel serves as Vice Chairman of the Board of Ipsen SA since August 30, 2005. He is also Chairman of the Company's Compensation Committee and Member of the Strategic Committee. Between 1995 and 2005, he worked for Coopers & Lybrand Corporate Finance (now PricewaterhouseCoopers Corporate Finance), becoming an Associate of the company in 1998. Mr. Flochel currently holds several other posts, including Director of Mayroy, Director of Beech Tree SA and Manager of Blue Hill Participations SARL, among others. Mr. Flochel is a graduate of Institut d'Etudes Politiques de Paris and holds a degree in Law from Universite Paris IX Dauphine. He also holds a Master of Science degree in Finance from the London School of Economics (University of London).

Aymeric le Chatelier

Mr. Aymeric le Chatelier serves as Chief Financial Officer, Executive Vice President at IPSEN SA. He started his career at Arthur Andersen audit firm in 1993. He became internal auditor first at Lagardere group in 1997 and then at Vivendi group in 1998. From 1999, he successively assumed several responsibilities in finance management in France and the United States within Veolia Environnement, notably as Deputy Chief Financial Officer of Veolia Water in 2004-2005. In 2006, he joined Arjowiggins group, a leading manufacturer of creative and technical paper, and was nominated Group Chief Financial Officer in 2009. In 2013, Mr. Aymeric Le Chatelier was nominated Financial Director of ERDF (electricity French distribution network company of EDF) and in 2014, he became member of the Management Board in charge of Finance and Sourcing within ERDF. He graduated from HEC.

Regis Mulot

Mr. Regis Mulot serves as Chief Human Resource Officer, Executive Vice President of IPSEN SA since March 13, 2018. He joins Ipsen from Staples Inc., the global specialty retail and e-commerce company, where he served as Executive Vice-President, Chief Human Resources Officer, leading a global team of over 600 professionals. Prior to his career with Staples (2009-18), Mr Mulot held HR leadership positions with Levi Strauss & Co (2002-08) and the technology start-up Broadnet Europe (2000-02), following earlier roles at GTECH Corporation (1994-2000), International Post Corporation (1991-94) and Chronopost SA (1989-91). Mr Mulot serves on the Board of Trustees, Simmons College (Boston M.A.); is Past Chairman of the Business Advisory Committee of the Simmons School of Management 2014-2017; Member of the French-American Chamber of Commerce, New England; and Founder and Chair of the French-American HR Forum since 2016. He has been Co-chair of the Boston CHRO (Chief Human Resources Officers) Leadership summit since 2014, and a Gartner CHRO Leadership Board member since 2017. Mr Mulot holds a DESS Entreprises Publiques (Master of Public Administration) from Universit Paris-Sud 11 in partnership with Paris IX-Dauphine and Institut International d’Administration Publique (IIAP). He also holds a Maîtrise Droit Public (Bachelor of Law) from Universite Paris II Pantheon-Assas, and is a Beta Gamma Sigma honoree from the Simmons College Chapter.

Alexandre LeBeaut

Mr. Alexandre P. LeBeaut serves as Executive Vice President Research & Development, Chief Scientific Officer at IPSEN SA since April 14, 2017. He joined the Company in 2013 as Senior Vice President, Chief Development Officer, Global Drug Development. Dr. Lebeaut earned his M.D. from Paris Diderot University and specialized in Pediatrics from Paris Descartes University. Before joining Ipsen, he held several global leadership positions in Clinical Development and Medical Affairs with biopharmaceutical companies including Axcan Pharmaceuticals, Sanofi, Novartis and Schering Plough Research Institute.

Dominique Laymand

Ms. Dominique Laymand serves as Executive Vice President, Chief Ethics and Compliance Officer of Ipsen SA since October 6, 2017. She was Senior Vice President, Chief Ethics and Compliance Officer at IPSEN SA until October 6, 2017. She is in charge of Ethics & Compliance strategy of Ipsen Group, the deployment of the Global Ethics & Compliance program and the organization of this department. This program is based on an integrated approach to prevention and management of operational risks, as well as on strong principles of integrity and ethics in the conduct of business. In a former role she acted as Vice-president Ethics & Compliance of Bristol Myers Squibb, setting up and managing the Ethics & Compliance Europe, Middle East, Africa, Turkey and Russia program. Ms. Dominique Laymand also chairs the committee of compliance of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and also the French Association of Pharmaceutical Industries (LEEM). She is the president of ETHICS, which is an association which includes International professionals of Ethics and Compliance, in the Healthcare sector.

Francois-Maurice Garnier

Mr. Francois-Maurice Henri Louis Garnier serves as Executive Vice President, General Counsel at IPSEN SA since 2014. He began his career in 1989 at Servier S.A. as International Contracts Manager and remained with the firm until September 1995. He then moved to Rhone Poulenc Rorer S.A. in 1995, to take up the position of Counsel for Corporate Transactions. In 1996 he moved to the United States as Associate Counsel, before being appointed Chief Counsel for France in 1999. Mr. Garnier continued his career as Chief Counsel at Aventis Animal Nutrition until 2001, when he joined the Pharmacia Group as Chief Counsel for Europe. He joined Pfizer France in 2003, as Vice-President, General Counsel before moving on to become Chief Counsel for Pfizer’s operations in Europe from 2009 to 2014. He was International Chief Counsel (outside the US) of Pfizer Inc. since January 2014. He graduated from the Universite Paris II Pantheon-Assas.

Dominique Bery

Ms. Dominique Bery serves as Executive Vice President, Strategy & Transformation of Ipsen SA since March 13, 2018. She spent the previous 18 years with McKinsey & Company, where she was elected Partner in 2010. Dominique co-led the Pharmaceuticals and Medical Products Practice in Europe and served multiple pharmaceutical and biotech companies. She also worked with diagnostics companies, hospitals, payors, ministries of health, patient associations, and public health organizations, gaining extensive experience in the healthcare industry. Located in Paris and Washington, Dominique led many company-wide transformation projects across Europe, US and Africa, working hand in hand with management and their teams. She supported clients to set their strategic priorities at corporate, business unit, and therapeutic area level, and she worked with a number of brand teams to accelerate brand performance. She brings a truly cross-functional perspective, having worked closely with most functions in pharmaceutical companies. In parallel, she initiated the creation of a community of women executives in France, focused on developing the capabilities of women executives on key business topics such as innovation, leadership in transformation, business model disruption. She is a graduate from ESSEC and holds a Masters of Business Administration from Harvard Business School.

Benoit Hennion

Mr. Benoit Hennion serves as Executive Vice President and President, Consumer Healthcare at IPSEN SA. Before joining Ipsen, he started his career at Societe Generale in the Czech Republic and then served for six years at the Paris office of Roland Berger Strategy Consultants. He joined Ipsen in 2006 within the Corporate Strategic Planning team. In 2009, he became Primary Care Business Unit Head for France, and subsequently, in 2011, General Manager of France Operations (including both Specialty Care and Primary Care). Following the split between Specialty Care and Primary Care in 2014, he was appointed Vice President, Asia-Pacific Specialty Care. He earned his MBA degree at ESSEC Business School (Paris, France).

Ivana Magovcevic-Liebisch

Dr. Ivana Magovcevic-Liebisch, Ph.D. J.D. serves as Executive Vice President, Chief Business Officer of Ipsen SA since March 13, 2018. She is in charge of Business Development, External Innovation and Strategic Alliances. She joins Ipsen from Axcella Health Inc., where she served as Executive Vice President, Chief Strategy and Corporate Development Officer. Prior to joining Axcella, Ivana was Senior Vice President and Head of Global Business Development at Teva Pharmaceutical Industries Ltd (2013-17), where she led and executed multiple business development transactions ranging from licensing to acquisition of drug candidates, commercial products and companies for the global specialty drug business. She previously worked at Dyax Corp (2001-13) in management roles of increasing scope and responsibility, including Executive Vice President and Chief Operating Officer. She began her biopharma career at Transkaryotic Therapies, Inc (1998-2001), where she was Director of Intellectual Property and Patent Counsel. Ivana serves as a member of the Board of Directors of Applied Genetic Technologies Corporation (AGTC), is also a member of the Board of Directors for Alivio Therapeutics, and was most recently appointed to the Board of Directors of Aeglea BioTherapeutics. Ivana is Trustee of Suffolk University, and an overseer of the Boston Ballet, Boston Museum of Science and Beth Israel Deaconess Medical Center. Ivana holds a Ph.D. in Genetics from Harvard University and received her J.D. in High Technology law from Suffolk University Law School. She graduated from Wheaton College with a B.A. in Biology and Chemistry. In 2008, Ivana was the winner of the Women Entrepreneurs in Science and Technology Leadership Award.

Aidan Murphy

Dr. Aidan Murphy serves as Executive Vice-President, Technical Operations of Ipsen SA since January 1, 2018. He has more than 25 years experience in the pharmaceutical and biotechnology industry, and since joining Ipsen in 2006 has held a number of manufacturing leadership roles in many countries. Since 2014 Dr. Murphy has held the position of Senior Vice President Biologics Development and Manufacturing at Ipsen. Also during his tenure at Ipsen, he has led the manufacturing sites of Tianjin (China), Dublin (Ireland), and Wrexham (UK) and occupied global roles as SVP CMC (Chemistry, Manufacturing, and Controls) Development & Engineering and Head of Specialty Care Manufacturing. He holds a Ph.D. in Organic Chemistry from Trinity College, Dublin.

Richard Paulson

Mr. Richard Paulson has been appointed Executive Vice President and Chief Executive Officer of Ipsen North America of Ipsen SA since February 5, 2018. During a 10-year career at Amgen, Richard Paulson held a number of positions in the company, including General Manager, Central and Eastern Europe, and subsequently General Manager Germany, before assuming leadership positions in Amgen's Oncology Business Unit. Prior to joining Amgen, he held international positions in general management, marketing and market access with Pfizer. He also served in a number of sales and marketing roles with increasing seniority for Glaxo Wellcome in Canada. He holds an MBA from the University of Toronto.

Harout Semerjian

Mr. Harout Semerjian serves as Executive Vice President & President, Specialty Care International & Global Franchises at IPSEN SA since February 2017. He has more than 23 years of pharmaceutical experience, including the last 17 years at Novartis focused on oncology and specialty care. He took on leadership roles with increasing responsibility across the U.S., Canada, Europe, Middle East & North Africa in addition to headquarter-based roles. His last role was Senior Vice President and Global Launch Head of ribociclib. Prior to that, he was Vice President and U.S. Hematology Franchise Head based in New Jersey. He holds dual MBA degrees from Cornell University, New York and from Queen’s University, Canada. He also holds a Bachelors degree of Science in Biology from the Lebanese American University.

Christopher Masterson

Mr. Christopher Masterson serves as Senior Vice President, Quality of IPSEN SA. He started with Ipsen in March 2015, based in the US, and following a period in the UK as head of the global Quality function moved back to the US to help build a US Quality hub for Ipsen. Chris’ experience spans over 20 years in the biopharma industry in increasingly senior global Quality positions for companies such as Shire, Abbott, Biogen, AstraZeneca and, most recently, at Cubist Pharmaceuticals (now Merck) in the US, where he was the global VP of Quality. Chris’ experience spans all good pharmaceutical practices, including GMP, GDP, GCP, GVP and GLP. He focus over the last decade has been in transforming, growing and improving Quality organizations to become not only globally compliant, but also delivering excellence and cross-functional working to optimize company performance and efficiencies. Building a Quality culture and embedded Quality mindset is his primary focus. Chris has been a member of the Parenteral Drug Society for the last 20 years. He is a respected leader and strategist in global Pharmaceutical Quality, and has led numerous successful health authority inspections with agencies including FDA, European agencies such as MPA (Sweden), MHRA (UK) and AIFA (Italy) as well as Irish, Brazilian, Japanese, Chinese and Middle East authorities. He is a microbiologist with a degree from the University of Massachusetts at Amherst in the USA.

Didier Veron

Mr. Didier Veron serves as Senior Vice President, Public Affairs and Corporate Communication at IPSEN SA. After beginning his career at the National Federation of Public Works, he has gained over 20 years of experience in the healthcare sector: primarily at the French Medicines Agency with his first CEO and then joining the pharmaceutical industry as a special advisor to the General Management of Ipsen. He is Member of the Board of Directors of Leem, the French Trade Association of Pharmaceutical Industries. Didier chairs the Public Affairs France / Europe Committee. He is also Secretary of the Strategic Committee of Healthcare Industries and Technologies. He is a lecturer at the Institut d’Etudes Politiques de Paris (Sciences Po Paris). He is a graduate of Sciences Po Paris and has a post-graduate degree in Health Law from Southern Paris University.

Eugenia Litz

Ms. Eugenia Litz serves as Vice President of Investor Relations at IPSEN SA. She started her career as a clinical research associate, focusing on cardiovascular and gastrointestinal therapeutic areas. In 2001, she became a market research analyst for Frost & Sullivan and then equity research analyst at Avondale Partners and at Thomas Weisel Partners. In 2006, she joined BioMarin Pharmaceutical, a listed US biotech company in California to create the Investor Relations function. Since 2014, she was Director, Investor Relations for AstraZeneca PLC in London (UK). She holds a BA in Biological Sciences from Northwestern University Illinois.

Heather White

Ms. Heather White serves as Vice President, Global Internal Audit at IPSEN SA since January 2014. She has worked in the pharmaceutical industry since 1984 acquiring a broad range of experience on an international level in a variety of roles. She started in sales and marketing (Organon, South Africa) before moving into clinical research (MSD UK). In 1997 she joined Schering-Plough UK and progressed to Head of Medical Affairs UK before relocating to Schering-Plough USA in 2002. Over the next six years she held various positions of leadership within SP Global Medical Affairs and Global Clinical Operations. In 2008 she moved to Amicus Therapeutics Inc., where, as Senior Director, she was responsible for overseeing the implementation of a quality management system and for initiating the development of a corporate compliance program to begin preparations for the company’s transition to commercial status. Within Ipsen, she is responsible for managing all activities of the Global Internal Audit department aimed at providing independent, objective and reasonable assurance that the major business risks are being managed appropriately, and assurance that the risk management and internal control frameworks are operating effectively. In this role she dual reports to the CEO and the CFO. She was qualified as a nurse-midwife before graduating from the University of Liverpool UK with a Masters in Clinical Research.

Christophe Jean

Mr. Christophe Jean serves as Special Advisor to the CEO of Ipsen SA since March 2018. He was Executive Vice President, Strategy Business Development of IPSEN SA until October 2, 2013. He joined the Company in September 2002, initially in charge of creating the strategic planning and strategic marketing departments. A graduate with a Masters of Business Administration degree from the Harvard University, he began his career in the pharmaceutical industry at Ciba-Geigy where he held several positions in marketing, sales and general management. Following the merger of Ciba-Geigy with Sandoz to form Novartis, he was made responsible for operations in Europe, the Middle East and Africa. In 2000, he became Chief Executive Officer of Pierre Fabre Medicaments. Currently, he also serves as Member of the Supervisory Board of Exonhit Therapeutics since October 2006, Chief Executive Officer of Ipsen Pharma SAS and Director of EBE (European Biopharmaceutical Enterprises).

Anne Beaufour

Ms. Anne Beaufour has been Director of Ipsen SA since August 30, 2005 and is also Chairman of the Company's Appointments and Governance Committee and Member of the Strategic Committee. She works as Vice Chairman of the Board and Deputy Director of Mayroy, Director and Chairman of the Board of Beech Tree SA, Manager of Highrock S.a.r.l. and Manager of Bluehill Participations S.a.r.l. Ms. Beaufour held several other posts, including Manager of SCI du 47, FinHestia, Henri-Heine, SCI Deux Chateaudun and SCI de la Fraternite, among others. She holds a Bachelors degree in Geology from Universite de Paris.

Henri Beaufour

Mr. Henri Beaufour has been Director of Ipsen SA since August 30, 2005 and is also Chairman of the Company's Strategic Committee. He holds a Bachelor of Arts degree from Georgetown University, Washington DC. He currently also works as Director of Mayroy SA and Director of Beech Tree SA. Mr. Beaufour previously held several other posts, including Manager of Camilia Holding, Beech Tree Sarl and FinHestia Sarl, among others.

Philippe Bonhomme

Mr. Philippe Bonhomme serves as Director - Representative of Mayroy SA at Ipsen SA since June 1, 2012. He is also Member of the Company's Ethics Committee. A graduate of Ecole des Hautes Etudes Commerciales, he is also a Certified Chartered Accountant. Mr. Bonhomme was Auditor and then Advisor for Mergers & Acquisitions at PricewaterhouseCoopers (formerly Coopers & Lybrand) from 1993 to 2005. Since 2005, he is Associated Director and Member of the Management Committee of Hottinguer Corporate Finance. He currently also works as Director of Mayroy SA.

Christophe Verot

Mr. Christophe Verot serves as Director of Ipsen SA since May 27, 2011. He is also Member of the Company's Audit Committee and the Appointments and Governance Committee. Apart from that he serves as Chairman of the Board of Directors of PwC Investissements SAS and also as Member of the Board of Directors of PwC Corporate Finance SAS. From 1985 to 1988, Mr. Verot was an auditor at Price Waterhouse. From 1988 to 1991, he was a consultant at SIAR, a Scandinavian consultancy firm on strategy. Since 1991, he has a consultancy activity in Corporate Finance then Valuation & Economics within PwC where he is a partner since 1995. Mr. Verot is a graduate of ESSEC Business School.

Carol Xueref

Ms. Carol Xueref serves as Director of Ipsen SA. She was Independent Director of Ipsen SA from June 1, 2012. She is also Independent Member of the Company's Strategic Committee and the Ethics Committee. Ms. Xueref graduated from Universite Paris II Pantheon-Assas with a Master of Legal Letters degree in Private Law and a DESS degree in International Commerce. She began her career working within Commercial Attache at the Embassy of Great Britain in Paris from 1982 to 1986. From 1986 to 1990, she was Head of Division within Chambre de Commerce International de Paris. She was then appointed as Director of Legal Affairs of Banque Populaire de la Region Ouest de Paris in 1990 and also served as Head of Legal Department of Credit Lyonnais from 1993 to 1996. Ms. Xueref was subsequently appointed as General Counsel of OIG. Since 1996, she has been Director of Legal Affairs and of Development, as well as Member of the Executive Committee at Essilor International. She is also Member of the college of Autorite de la Concurrence since 2006 and Founder, Member and former Chairwoman of Cercle Montesquieu, an association of Legal Affairs Directors (1998-2002). She is currently General Secretary and Director of Association Francaise des Femmes Juristes and also Director of Association des Juristes Franco-Britanniques. Ms. Xueref works as Director of several foreign subsidiaries of Essilor International as well.

Helene Auriol-Potier

Ms. Helene Auriol-Potier serves as Independent Director of Ipsen SA. Since October 2016, she is General Manager Public Sector Europe of West of Microsoft. Hélène Auriol-Potier has built a career in the digital technologies and telecommunications in the United States, Europe, Africa and Asia. She began her career at New York at France Telecom in 1986. In 1990, she joined the mobile technology company Nortel, where she spent 16 years and held various management positions, including as Vice President Mobile Pre-Sales and Vice President EMEA, Services & Operations. In 2006, she joined Dell as Managing Director for Africa and the Mediterranean Zone and Member of the Executive Committee, Dell Emerging Markets. In 2009, Microsoft recruited her as Director General, Enterprise, Public Sector and Partners and Member of the Executive Committee from Microsoft France. Then she was appointed President of Microsoft Singapore and Member of Executive Committee of Microsoft Asia-Pacific. She is a graduate of the Ecole Nationale Superieure des Telecommunications and an Executive Program at INSEAD.

Herve Couffin

Mr. Herve Couffin has been Independent Director of Ipsen SA since August 30, 2005. He is also Independent Member of the Company's Appointments and Governance Committee and the Audit Committee. He currently also holds several other posts, including Co-Manager of Conseil SARL, Director of Compagnie Franco-Tunisienne des Petroles and Chairman of the Supervisory Board of Mersen, among others. He is Chairman of Callisto SAS, a consulting company. Between 1998 and 2004, Mr. Couffin was Member of the Executive Committee and Senior Partner of PAI Partners. Prior to this, he spent 15 years with Paribas. Mr. Couffin is a graduate of Ecole Polytechnique and obtained a degree in Engineering from Ecole des Mines de Paris.

Margaret Liu

Dr. Margaret A. Liu, M.D. serves as Independent Director of Ipsen SA June 7, 2017. She is currently a consultant in the fields of health, vaccines and Immunotherapy, for pharmaceutical / biotechnology companies, companies institutions, universities, and government scientific research committees. She is Professor at the Karolinska Institute in Stockholm, Sweden since 2003, first as as Visiting Professor, then currently as Foreign Adjunct Professor (Associate Professor in a foreign capacity). She is also Adjunct Full Professor (Full Professor Associate) at the University of California at San Francisco since 2013 and President of the International Society for Vaccines since 2016. She previously held various positions in the private and public sectors in parallel with her academic career. From 1984 to 1988, she was Visiting Scientist (Visiting Scholar) at Massachussetts Institute of Technology. From 1987 to 1989 she was Instructor of Medicine (Instructor in medicine) at Harvard University. From 1989 to 1995, she was Adjunct Assistant Professor of Medicine (Associate Professor of Medicine) at the University of Pennsylvania at Philadpelphie. From 1990 at 1997, she was Director, then Senior Director of the Viral and Cell Biology Division at the Laboratories Merck. From 1997 to 2000, she was Vice-President of Research for the Vaccines and Vice-President of the Vaccines and Gene Therapy division of Chiron Corporation in Emeryville, California. From 2000 to 2002, she was Senior Advisor (Senior Consultant) in Vaccinology for the Bill & Melinda Gates Foundation. From 2000 to 2006, she was Vice President of the Board of Transgene in Strasbourg, France. From 2005 to 2009, she was Director of Sangamo Biosciences Inc. She is a recognized scientist in the field of research and development in vaccines and vaccination programs against infectious diseases, in particular HIV and in the field of gene therapies. She holds a B.Sc. in Chemistry with honors from Colorado College and a Ph.D. from Harvard Mediccal School.

Pierre Martinet

Mr. Pierre Martinet serves as Independent Director of Ipsen SA since September 19, 2005 and is also Independent Member of the Company's Compensation Committee, as well as Chairman and Independent Member of the Audit Committee. A graduate of Ecole Superieure de Commerce de Paris, he also holds an MBA degree from the Columbia Graduate School of Business (Columbia University). He was Member of the Board of Directors and of Sequana Capital (formerly Worms & Cie), where he also served as Appointed Managing Director until 2007. He was also Appointed Director of Groupe Exor. Prior to joining the Company, Mr. Martinet was General Secretary of Cartier between 1977 and 1986, Member of an investment fund management team at Paribas Technology from 1986 to 1990, Member of the Management Team of Pallas Venture (a company he co-founded) and Executive at Perrier between 1990 and 1992. He currently also works as Deputy Director of Old Town SA and Chairman of Almacantar.

Michele Ollier

Ms. Michele Ollier serves as Independent Director of Ipsen SA since May 27, 2015. Since February 1, 2016, she is one of the partners and one of the founding members of Medicxi, a venture capital company based in Geneva and London. Medicxi Ventures is the spin-off of the entire life sciences activity of Index Ventures. From February 2006 to February 2016, she was a partner in the investment team in life sciences at Index Ventures. From 2003 to 2006, she was Director of Investment at Edmond de Rothschild Investment Partner in Paris. From 2000 to 2002, she was Vice President Corporate at Serono International. From 1994 to 2000, she held various positions within Rhône-Poulenc Rorer, notably in oncology and within the gene therapy division, RPR Gencell. Previously, she held various positions in charge of strategy, development and marketing in the pharmaceutical companies Sanofi International and Bristol-Myers Squibb France. She graduated from the Faculty of Medicine of Paris-Ouest

Carol Stuckley

Ms. Carol Stuckley serves as Independent Director of Ipsen SA since June 7, 2017. She is currently CFO and Senior Vice President of Healthcare Payment Specialists, LLC in Fort Worth, Texas. Healthcare Payment Specialists offers to hospitals and health systems in the United States technological tools in order to meet their needs for compliance and management of medical care and the government third-party payer. Between 2010 and 2013, she was Vice President, Finance (Chief Financial Officer) North America from Galderma Laboratories, LP, to Fort Worth, Texas. Before Galderma, She spent 23 years at Pfizer, Inc. in New York, where she held various international positions within financial departments such as Assistant Treasurer, Officer and Vice President Finance. She holds an MBA in International Business & Finance and a Master's degree in Economics of the Temple University (Fox Business School) in Philadelphia, as well as a license in Economics and French from the University of Delaware in Newark. Mandates and functions in progress.